Avidity Partners Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Avidity Partners Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Buy	+100,000	New	+$1.66M	0.19%	38
2025 Q3	–	Sell	-39,000	Closed	-$1.84M	–	55
2025 Q2	$1.84M	Buy	+39,000	New	+$1.59M	0.37%	49
2023 Q4	–	Sell	-777,172	Closed	-$44.3M	–	82
2023 Q3	$44.3M	Buy	777,172 +377,172	+94%	+$20.8M	1.78%	19
2023 Q2	$20.4M	Buy	+400,000	New	+$10.8M	0.71%	51
2022 Q2	–	Sell	-400,000	Closed	-$4.44M	–	92
2022 Q1	$4.44M	Hold	400,000	–	–	0.1%	76
2021 Q4	$3.96M	Hold	400,000	–	–	0.08%	85
2021 Q3	$3.94M	Hold	400,000	–	–	0.1%	91
2021 Q2	$4.14M	Hold	400,000	–	–	0.11%	98
2021 Q1	$4.08M	Hold	400,000	–	–	0.11%	87
2020 Q4	$4.55M	Buy	+400,000	New	+$4.25M	0.15%	83

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Weiss Asset Management Boston, Massachusetts $5.43B AUM 42.42% 1-Year Est. Return

Logos Global Management San Francisco, California $1.94B AUM 444.09% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return